Published in Gene Therapy Weekly, October 11th, 2001
"We and others have recently shown that a novel class of mixed-backbone oligonucleotides targeting the protein kinase A type I (PKAI) subunit of RI alpha exhibits improved pharmacokinetic properties and antitumor activity accompanied by increased apoptosis in several human cancer types in vitro and in vivo," remarked G. Tortora and colleagues, University of Naples Federico II, in Clinical Cancer Research.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.